Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
On Monday, Piper Sandler reaffirmed its confidence in BioCryst Pharmaceuticals (NASDAQ:BCRX), maintaining an Overweight rating on the company’s stock with a steady price target of $23.00. The endorsement follows BioCryst’s recent financial disclosure, where the company reported a Q4 2024 revenue of $124.2 million for its Orladeyo treatment, slightly surpassing the $123.5 million preliminary figure released last month. The company has demonstrated strong momentum, with a 61.3% return over the past year and impressive revenue growth of 29.92% in the last twelve months.According to InvestingPro data, BioCryst maintains a healthy financial position with a current ratio of 2.78, indicating strong liquidity to meet short-term obligations.
The firm’s analysts highlighted the company’s upward revision of its FY25 revenue guidance for Orladeyo, increasing by $17.5 million at the midpoint, driven by anticipated benefits from the Inflation Reduction Act (IRA). This amendment underscores a positive outlook for the drug’s commercial performance.
BioCryst’s strategic investments in its pipeline, particularly in BCX1777 for Netherton syndrome and avoralstat for diabetic macular edema (DME), were noted as elements sustaining the company’s path to profitability. Despite these investments, the company’s commercial franchise and burgeoning pipeline of innovative therapies are seen as encouraging signs.
Piper Sandler expressed a favorable view on BioCryst’s valuation, citing the stock’s current trade at approximately three times the projected 2025 revenue guidance. The firm perceives this as an attractive entry point with limited speculation on acquisition premiums. The analysts concluded by reiterating their recommendation for investors to buy BioCryst shares, emphasizing the company’s robust commercial potential and promising clinical developments. InvestingPro analysis shows the stock is currently fairly valued, with analyst targets ranging from $8 to $30, and the platform’s Financial Health Score rates the company as "GREAT" with a score of 3.07.For deeper insights into BioCryst’s valuation and growth prospects, including 8 additional ProTips and comprehensive financial analysis, check out the full Pro Research Report available on InvestingPro.
In other recent news, BioCryst Pharmaceuticals reported its fourth-quarter 2024 earnings, revealing a mixed financial performance. The company posted a loss per share of $0.13, missing the analyst forecast of $0.07. However, BioCryst’s revenue for the quarter exceeded expectations, reaching $131.53 million compared to the anticipated $127.17 million, driven by strong sales of its key product, Orladeyo. Despite the earnings per share miss, the company has raised its 2025 revenue guidance, projecting total revenue between $560 million and $575 million, and Orladeyo revenue between $535 million and $550 million.
BioCryst also achieved a non-GAAP operating profit of $62.9 million for the full year 2024, a significant improvement from the previous year’s loss. JPMorgan analyst Jessica Fye maintained an Overweight rating on the company, highlighting the positive reception of the upward guidance revision for Orladeyo revenues. The company is optimistic about its financial outlook for 2025, expecting to approach positive earnings per share and cash flow in the latter half of the year. Additionally, BioCryst’s progress in its rare disease pipeline, including successful pediatric trials for Orladeyo, indicates promising product development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.